Ahmedabad-based Intas Pharmaceuticals has signed an exclusive partnership with Pune-headquartered IntegriMedical to introduce India’s first needle-free injection system for IVF and gynaecology treatments. This collaboration leverages IntegriMedical’s proprietary Needle-Free Injection System (N-FIS) to deliver hormones and medications painlessly, addressing injection-related anxiety and improving patient compliance.
Glimpse:
Announced in late December 2025, the deal positions Intas as the pioneer in offering needle-free therapies for reproductive health in India. The N-FIS uses high-pressure jet stream technology for precise, subcutaneous/intramuscular delivery without needles reducing pain, phobia, and risks like needle-stick injuries. This is particularly impactful for IVF patients enduring frequent injections, potentially enhancing treatment adherence amid India’s booming fertility sector.
Intas Pharmaceuticals Ltd., a leading Indian multinational, has entered into an exclusive agreement with IntegriMedical Pvt. Ltd. to bring revolutionary needle-free injection technology to IVF and gynaecology treatments across India. This partnership marks Intas as the first and only company in the country to offer such advanced, patient-centric drug delivery for reproductive care.
IVF and gynaecological therapies often involve multiple daily injections over weeks, leading to significant pain, anxiety, needle phobia, and treatment fatigue issues that can affect compliance and outcomes. IntegriMedical’s Needle-Free Injection System (N-FIS) addresses these challenges head-on with a spring-powered, high-velocity jet stream mechanism that disperses medication uniformly under the skin in a spray-like pattern, eliminating needles entirely.
The technology ensures consistent, predictable delivery while minimizing discomfort, tissue damage, and risks associated with traditional syringes. It is particularly suited for hormone administration in fertility treatments, where precision and patient comfort are critical.
Under the agreement, Intas and IntegriMedical will collaborate to roll out N-FIS across IVF clinics and gynaecology centers nationwide, streamlining access and training for healthcare providers. This move aligns with growing demand for innovative, fear-free solutions in women’s health, potentially benefiting hundreds of thousands of patients annually.
IntegriMedical, backed by a 20% stake from Serum Institute of India, has already gained traction in paediatrics and vaccinations with N-FIS (launched in 2024). Expanding into gynaecology and IVF represents a natural progression, supported by regulatory approvals (CDSCO, CE, ISO 13485).
Intas, known for its strong portfolio in women’s health and oncology, sees this as a step toward redefining therapeutic experiences through innovation.
“This collaboration represents a decisive step in transforming how reproductive care is delivered, reducing injection-related discomfort and anxiety while enhancing compliance and patient satisfaction.”
By
HB Team
